Asthma is a chronic inflammatory disease of the airways that causes recurrent episodes of wheeze, breathlessness, chest tightness, and cough. Symptoms can vary over time and are often triggered by allergens, infections, exercise, or irritants.
Fire and medical officials warn that glutathione, a supplement offered to wildland firefighters exposed to toxic smoke, is unproven and potentially unsafe. At least two pharmacies recalled the supplement due to bacterial contamination. The International Association of Firefighters issued a safety advisory noting it is not FDA-approved.
A Chest study finds that respiratory or red flag symptoms at baseline increase the likelihood of lung cancer diagnosis within one year after screening. A Nature study identifies glucocorticoid-related genes with causal links to non-small cell lung cancer and constructs a multi-omics prognostic model.
New research shows GLP-1 receptor agonists are associated with reduced asthma exacerbation risk in overweight, obese, and morbidly obese patients without diabetes, with risk reductions of 14.6%, 12.2%, and 13.3% respectively. The findings were presented at the 2026 AAAAI Annual Meeting.
FDA approved AstraZeneca's Breztri Aerosphere for asthma; EU CHMP recommended Trixeo. Phase 3 KALOS/LOGOS trials showed improved lung function and reduced severe exacerbations versus dual therapy.
A real-world study in Galicia showed nirsevimab reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second. The RSV prevention market is expanding to cover high-risk children, with Beyfortus the only antibody approved for second-season use. The FDA has cited Sanofi for misleading promotional claims about the product.
AstraZeneca published a large-scale CNV analysis in Nature and partnered with Helix for clinico-genomic data. Quotient Therapeutics is using somatic genomics to identify disease-relevant mutations.
Studies reveal how kinin receptor antagonists achieve subtype selectivity and identify BDNF as a direct TLR4 antagonist, highlighting BDP-12 as a potential therapy for acute inflammatory diseases.
Sanofi announces leadership transition with CEO departure and interim appointment, while reporting key regulatory milestones including FDA Breakthrough Therapy designation for venglustat and expanded Dupixent approvals. The company advances an observational RSV study in Australia and outlines strategic initiatives in AI drug discovery and potential consumer healthcare spin-off.
Kymera Therapeutics presented Phase 1 data for oral STAT6 degrader KT-621 in healthy Japanese adults, showing ≥98% STAT6 degradation and favorable safety. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected in 2027, and FDA has granted Fast Track designation for both indications.
Recent research identifies hidden systemic inflammation in primary ciliary dyskinesia via oral swab and confirms asthma biologics do not increase respiratory infection risk in pediatric patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07815925 |
Childhood Infection and Immunity Longitudinal Cohort |
NOT_YET_RECRUITING | |
| NCT07807007 |
Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma |
COMPLETED | PHASE2 |
| NCT07804303 |
Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants |
COMPLETED | PHASE1 |
| NCT07792395 |
Ginger's Therapeutic Potential in Asthma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07792330 |
Asthma Lung Sounds With Wearable Stethoscope |
NOT_YET_RECRUITING | NA |
| NCT07791147 |
Family-centred Pulmonary Rehabilitation to Empower Carers |
NOT_YET_RECRUITING | NA |
| NCT07790159 |
Budesonide/Formoterol Inhalation Powder in Adults With Asthma |
COMPLETED | PHASE3 |
| NCT07787507 |
Withania Somnifera for Moderate-to-Severe Persistent Asthma |
COMPLETED | NA |
| NCT07787117 |
QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol |
NOT_YET_RECRUITING | |
| NCT07782996 |
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2) |
NOT_YET_RECRUITING | PHASE3 |
